» Articles » PMID: 19376882

How to Assess the External Validity of Therapeutic Trials: a Conceptual Approach

Overview
Journal Int J Epidemiol
Specialty Public Health
Date 2009 Apr 21
PMID 19376882
Citations 83
Authors
Affiliations
Soon will be listed here.
Abstract

Background: External validity of study results is an important issue from a clinical point of view. From a methodological point of view, however, the concept of external validity is more complex than it seems to be at first glance.

Methods: Methodological review to address the concept of external validity.

Results: External validity refers to the question whether results are generalizable to persons other than the population in the original study. The only formal way to establish the external validity would be to repeat the study for that specific target population. We propose a three-way approach for assessing the external validity for specified target populations. (i) The study population might not be representative for the eligibility criteria that were intended. It should be addressed whether the study population differs from the intended source population with respect to characteristics that influence outcome. (ii) The target population will, by definition, differ from the study population with respect to geographical, temporal and ethnical conditions. Pondering external validity means asking the question whether these differences may influence study results. (iii) It should be assessed whether the study's conclusions can be generalized to target populations that do not meet all the eligibility criteria.

Conclusion: Judging the external validity of study results cannot be done by applying given eligibility criteria to a single target population. Rather, it is a complex reflection in which prior knowledge, statistical considerations, biological plausibility and eligibility criteria all have place.

Citing Articles

If things were simple, word would have gotten around. Can complexity science help us improve pediatric research?.

Fustolo-Gunnink S, de Boode W, Dekkers O, Greisen G, Lopriore E, Russo F Pediatr Res. 2024; .

PMID: 39609614 DOI: 10.1038/s41390-024-03677-4.


Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population.

Jakobsson M, Strambi A, Nilsson F, Arpegard J, Dalen J Future Oncol. 2024; 20(20):1385-1392.

PMID: 39057291 PMC: 11376413. DOI: 10.1080/14796694.2024.2351352.


Designing target trials using electronic health records: A case study of second-line disease-modifying anti-rheumatic drugs and cardiovascular disease outcomes in patients with rheumatoid arthritis.

Rivera A, Pierce J, Sinha A, Pawlowski A, Lloyd-Jones D, Lee Y PLoS One. 2024; 19(6):e0305467.

PMID: 38875273 PMC: 11178161. DOI: 10.1371/journal.pone.0305467.


Methods for pragmatic randomized clinical trials of pain therapies: IMMPACT statement.

Hohenschurz-Schmidt D, Cherkin D, Rice A, Dworkin R, Turk D, McDermott M Pain. 2024; 165(10):2165-2183.

PMID: 38723171 PMC: 11404339. DOI: 10.1097/j.pain.0000000000003249.


Patient-reported outcomes and symptom clusters pattern of chemotherapy-induced toxicity in patients with early breast cancer.

Wiranata J, Hutajulu S, Astari Y, Leo B, Bintoro B, Hardianti M PLoS One. 2024; 19(2):e0298928.

PMID: 38394281 PMC: 10890761. DOI: 10.1371/journal.pone.0298928.